Highlights
- Third quarter 2026 net loss was $55.7 million, compared with a net loss of $35.5 million a year earlier.
- Research and development expense was $44.1 million for the quarter, compared with $27.3 million a year earlier.
- Management said it ended the third quarter with approximately $953 million in cash and investments, with no debt.
- Management expects 2026 Research and Development expense of $185 million to $200 million, general and administrative expense near $65 million.
Nektar Therapeutics (NASDAQ:NKTR) shares were trading at USD 30.96 on November 20, 2026, down 4.86%, with a relative Volume at time of 2.70. The clinical-stage biotechnology company held its third quarter 2026 Earnings Call on November 13 and filed its Quarterly Report for the period ended September 30, 2026 the same day.
Nektar Therapeutics is a Delaware corporation with principal executive offices in South San Francisco, California. It is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases through immunomodulatory agents. Its pipeline includes rezpegaldesleukin, NKTR-0165 and NKTR-0166, which target autoimmune diseases. The company reports Revenue from non-cash royalties related to the sales of future royalties, and its financial statements are presented on a calendar fiscal year ending December 31.
Third Quarter 2026 Results
For the three months ended September 30, 2026, total revenue was $9.4 million, compared with $11.8 million a year earlier. Revenue consisted of non-cash Royalty revenue related to the sales of future royalties.
Research and development expense was $44.1 million, compared with $27.3 million. General and administrative expense was $24.6 million, compared with $16.1 million. The loss from operations was $57.8 million, compared with $31.7 million.
Net loss was $55.7 million, compared with $35.5 million. Basic and diluted net loss per share was $1.63, compared with $1.87.
Nine-Month Results and Cash Flow
For the nine months ended September 30, 2026, total revenue was $30.4 million, compared with $33.4 million. Research and development expense was $118.9 million, compared with $87.6 million, and general and administrative expense was $50.8 million, compared with $57.5 million. The loss from operations was $139.2 million, compared with $112.4 million.
Net loss was $141.2 million, compared with $128.0 million. Basic and diluted net loss per share was $4.60, compared with $8.14. Net cash used in Operating Activities was $192.0 million, compared with $143.6 million.
Balance Sheet
Cash and cash equivalents were $34.7 million at September 30, 2026, compared with $15.1 million at December 31, 2025. Short-term investments were $579.7 million, compared with $230.6 million, and Long-Term Investments were $338.5 million, compared with none at December 31, 2025.
Total Assets were $1.04 billion, compared with $280.4 million. Total liabilities were $187.5 million, compared with $190.6 million, and total stockholders' Equity was $849.7 million, compared with $89.8 million.
Pipeline Progress and Outlook
On the November 13, 2026 call, management said the third quarter advanced rezpegaldesleukin, called REZPEG, into phase 3 studies. It said the global phase 3 studies in atopic dermatitis have started, that the phase 3 study in alopecia areata is on track to start in December, and that it anticipates first top-line data readouts for the atopic dermatitis studies in the summer of 2028. Management said the ZENITH-AD program includes three pivotal studies with 510 patients aged 12 years or older in each study, and that all three have been initiated.
On financial guidance, management said it ended the third quarter with approximately $953 million in cash and investments, with no debt. It said it now expects to end 2026 with more than $840 million in cash and investments, compared with the range of $815 million to $840 million provided on the second quarter call.
Management said it expects full-year 2026 research and development expense of $185 million to $200 million, which includes approximately $5 million to $10 million of non-cash Depreciation and stock-based compensation expense. It said it expects fourth quarter research and development expense to increase and full-year general and administrative expense to be approximately $65 million. Management also said it expects non-cash royalty revenue of approximately $38 million for the year.






Please wait processing your request...